Experimental Dual-Target CAR t therapy takes on Hard-to-Treat blood cancers
NCT ID NCT04162353
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 23 times
Summary
This early-phase study tests a new type of cell therapy (BCMA-CD19 cCAR) in 12 people with multiple myeloma or plasmacytoid lymphoma that has returned or not responded to standard treatments. The main goal is to see if the therapy is safe and tolerable. Participants receive a single infusion of their own modified immune cells designed to attack two cancer targets.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chengdu Military General Hospital
RECRUITINGChengdu, Sichuan, China
Contact Email: •••••@•••••
-
Peking University Shenzhen Hospital, China
RECRUITINGShenzhen, Guangdong, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.